• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schick delisted from Nasdaq

Article

Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schick’s common stock would no longer be

Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schick’s common stock would no longer be traded on the exchange. The panel attributed its decision to Schick’s inability to file its 10-K for fiscal 1999 (end-March) on time, as well as factors discussed in Schick’s 8-K, filed on Sept. 2.

Schick will request a review of the panel’s decision within the 15-day limit required by Nasdaq’s marketplace rules, and plans to file its 10-K and its 10-Q for the quarter ended June 30 as soon as the firm’s new accountants, Grant Thornton, complete their audit of Schick’s financial statements. Schick’s former accounting firm, PricewaterhouseCoopers, resigned as the company’s independent accountants on Aug. 25. Schick will seek relisting on the exchange, or apply for listing on another exchange, once its filings are current with the Securities and Exchange Commission, according to the Long Island City, NY-based company.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.